Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
Add to watchlist
62.00+2.10 (+3.51%)
At close: 05:29PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close59.90
Open56.40
Bid60.00 x 0
Ask62.00 x 0
Day's Range56.40 - 63.90
52 Week Range47.10 - 82.90
Volume3,613
Avg. Volume3,201
Market Cap696.024M
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-6.41
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est300.00
  • GlobeNewswire

    FDA approves Infant Bacterial Therapeutics' request for a new orphan drug designation

    Building upon Infant Bacterial Therapeutics AB’s (IBT) unique expertise in developing treatment solutions for preterm infants, IBT is at an early stage of investigating the possibilities of developing a drug to prevent retinopathy of prematurity, a growing and serious condition that often leads to blindness among prematurely born babies. The FDA granted orphan drug designation for IBT’s product on Sep 20th . Retinopathy of prematurity affects 50-70% of preterm infants weighing less than 1,500 gr

  • GlobeNewswire

    Infant Bacterial Therapeutics AB (publ) Interim Management Statement January 1-June 30, 2022

    Message from the CEO Our IBP-9414 clinical phase III development program is progressing well. We have seen an overall acceleration of recruitment rates and, as mentioned previously, have been working on numerous activities to expedite the execution of our study. It is particularly satisfying to note that the recruitment momentum is picking up at the European hospitals. Today, we have recruited 1,102 children, thus slightly more than half of the children that we will include in the study. During

  • GlobeNewswire

    Infant Bacterial Therapeutics AB appoints Maria Ekdahl as CFO

    Press Release June 30, 2022 Infant Bacterial Therapeutics AB (publ) announced today that Maria Ekdahl has been appointed Chief Financial Officer (CFO) effective September 19, 2022. She will be part of the Management Team and report to Staffan Strömberg, CEO of IBT. Maria, who has a Master's degree in economics from Linnaeus University, comes to IBT from the Swedish Film Institute where she served as CFO. She brings with her an extensive financial background from organizations including Telenor,

Advertisement
Advertisement